Trialbee is collaborating with clinical research organisation (CRO) Ergomed to act as the patient recruitment platform for the latter’s newly unveiled Rare Disease Innovation Center.

The collaboration will merge Trialbee Real-World Data (RWD) with Ergomed’s new Site Advantage solution to boost recruitment of patients with rare diseases. 

Furthermore, the partnership will enable improved patient centricity in developing new therapies for rare diseases and bringing them to market rapidly and with reduced costs.

The Site Advantage operating model of Ergomed is tailored to offer support to research sites and patients who are taking part in clinical research for rare diseases. 

The centre will leverage Trialbee’s RWD-powered recruitment engine as well as a SaaS-based enrolment platform for the detection, recruitment and enrolment of subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the Rare Disease Innovation Center, which offers complete trial management services for the largest pharmaceutical firms across the globe, will use Trialbee as its patient identification partner.

Ergomed will leverage the Trialbee Hive solution to enhance referrals and identify patients in an effective manner compared to standard site-based recruitment. 

To boost transparency and inclusivity by tracking referrals at sites, Trialbee Honey will be utilised. 

Trialbee Honey is an end-to-end approach that improves recruitment irrespective of geography or epidemiology.

Trialbee CEO Matt Walz said: “This partnership is about impacting global rare disease research in a meaningful way for our industry.

“By providing a global patient referral ecosystem with Trialbee Hive, triaged through a single onboarding platform with Trialbee Honey and fully enabled by Ergomed Site Advantage, we provide patients a frictionless journey into clinical research for rare disease, while reducing the enrolment on sites.”

In October last year, Trialbee introduced a new centralised software platform designed for recruitment teams to speed up subject recruitment timelines in trials.